Parkinson's disease therapies Tasmar (tolcapone) and Sinemet CR (sustained-release carbidopa-levodopa) will be co-promoted for three years in the U.S. Roche's Tasmar, approved Jan. 29, is indicated for use as an adjunct to carbidopa and levodopa therapy. Over 500 Roche reps and a "few hundred" DuPont reps will promote the compounds. The co-promotion agreement provides additional support to DuPont's second top-selling Rx product line as the company forges an independent presence after the dissolution of the DuPont Merck joint venture. DuPont says the agreement with Roche will not affect the profit equalization formula of its license of the antihypertensives Cozaar/Hyzaar to Merck: the formula takes into account sales of the Sinemet line as well as Cozaar/Hyzaar sales and spending
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth